Anti-PI3 Kinase p110 beta Polyclonal Antibody for WB and ELISA - P42338

Core Product Specifications and Parameters

Biological Background: PI3 Kinase p110 beta Function and Localization

• The PI3 Kinase p110 beta (PIK3CB/PIK3C1) is the 110 kDa catalytic subunit of class IA phosphoinositide 3-kinase, responsible for converting phosphatidylinositol 4,5-bisphosphate (PIP2) into the second messenger phosphatidylinositol 3,4,5-trisphosphate (PIP3). Related references:
  PMID:15135396
• It acts downstream of G protein-coupled receptors (GPCRs) and receptor tyrosine kinases, crucially activating AKT1 and regulating cell growth, survival, proliferation, and migration.
• p110 beta is essential for platelet adhesion and aggregation, transducing signals from GPCRs, integrin αIIbβ3, and ITAM-bearing receptors, and is required for thrombus formation and stability.
• In addition to its lipid kinase activity, p110 beta possesses intrinsic serine/threonine protein kinase activity and undergoes autophosphorylation, which may modulate its scaffolding functions. Related references:
  PMID:12502714
• The protein localizes to both the cytoplasm and the nucleus, suggesting it participates in signaling events at multiple subcellular sites.
• p110 beta also contributes to autophagy by modulating PtdIns3P levels and activating the VPS34 complex, and can function as a scaffold protein in insulin signaling, independent of its kinase activity.
• Aberrant activation of PI3K p110 beta is frequently associated with oncogenesis, particularly in PTEN-deficient tumors and models driven by ERBB2 or RAS mutations, highlighting its therapeutic relevance.
• PIK3CB mRNA is ubiquitously expressed across human tissues, consistent with its fundamental roles in cellular physiology.

Experimental Guidance and Technical Tips

• The immunogen is a recombinant fusion protein spanning amino acids 410–600 of human PIK3CB, a region located within the catalytic domain; such design generally yields antibodies capable of recognizing the full-length endogenous protein.
• The predicted specificity is supported by the antibody's cross-reactivity with mouse and rat PI3K p110 beta, which share high sequence homology in the targeted region.
• For Western blot, expect a band at approximately 123 kDa; consider testing whole-cell lysates from cell lines with known PIK3CB expression (e.g., HeLa, MCF7, or platelet lysates) and optimize transfer and blocking conditions.
• In ELISA applications, use the antibody as a capture or detection reagent; validate pairing with antigen and appropriate secondary antibodies in the intended assay format.
• As a polyclonal antibody, performance may vary between lots; always include positive and negative controls and titrate the antibody to determine the optimal working concentration for your specific samples.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio provides diagnostic manufacturers, labs, and research institutes with one-stop access to IVD raw materials, technical services, and consulting from concept to clinic. This anti-PI3 Kinase p110 beta polyclonal antibody supports research into PI3K/AKT signaling, cancer biology, and thrombosis, and is part of our extensive catalog of validated antibodies. Beyond individual reagents, we offer bulk ancillary reagents, optimized antibody pairs, and custom sourcing of rare targets to streamline your development pipeline.